Tetrous earned a U.S. patent related to its EnFix family of demineralized cortical bone fiber implants, according to a Jan. 13 news release.
The new patent protects the application of EnFix DBF technology for enthesis reformation. The platform leverages a proprietary form of demineralized bone fiber for osteoinductivity, osteoconductivity and biolgic healing.
This is the sixth U.S. patent secured for the EnFix family of implants and their manufacturing.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
